Sythentic biotechnology company developing biosynthetic platform to speed development of cannabinoid and psychedelic therapeutics Octarine Bio announced having expanded its scientific advisory board.
This expansion entails addittin of new members to its scientific advisory board to help the company navigate deeper in psychedelics research space. The scientific board has added four high ranking and prolific names in the medical industry namely; Prof. Birger Lindberg-Møller, Prof. Jo Neill, Dr Henrik Klitgaard and Dr Claire Foldi.
The company announces this expansion following its latest financing round in which it fetched $3.2 million to help it rapidly expand its operations and advance its cannabinoid glycoside program through pre-clinical testing.
The company’s co-founder and chief scientific officer, Nick Milne, says as a company they are humbled to welcome the new highly respected members on the board further adding their knowledge and expertise will be used to propel the company to greater heights.
“As Octarine advances its drug discovery programs through pre-clinical and clinical development, it’s vital for us to have a diverse background of scientific expertise we can call on to guide us through this process. We are humbled that such highly-respected and world-renowned experts believe in our mission and have agreed to join us. We look forward to using their wealth of knowledge and expertise in the future,” said Milne.